Literature DB >> 22855362

Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas.

Yi-Li Zhou1, Chao Liu, Xuan-xuan Dai, Xiao-Hua Zhang, Ou-Chen Wang.   

Abstract

Correlation between clinicopathogenetic features and the expression of specific miRNAs is unclear in papillary thyroid carcinoma (PTC). We therefore sought to assess whether miR-221 was associated with aggressive clinicopathologic characteristics and the BRAF mutation. We studied the expression levels of miR-221 using northern blot quantitated by scion image in 51 cases of PTCs. The status of BRAF of PTCs was analyzed through direct DNA sequencing. Mann-Whitney U test was used to analyze different expression of miR-221 in PTCs with distinct clinicopathogenetic characteristics including gender, age, tumor size, multifocality, extrathyroidal invasion, disease stages, node metastasis, and BRAF status. Compared with the normal thyroid tissues, the relative expression of miR-221 in tumor tissues was significantly upregulated (p < 0.001). Overexpression of miR-221 was significantly associated with extrathyroidal invasion (p = 0.001), lymph node metastasis (p = 0.046), advanced disease stages III-IV (p = 0.001), and the BRAF mutation (p = 0.014). While among BRAF wild tumors, miR-221 was only associated with extarthyroidal invasion, it showed strong association with all above aggressive features among BRAF mutation tumors. MiR-221 may be of potential importance in determining the aggressive properties of PTCs including the BRAF mutation, and it may further refine the risk stratification by BRAF mutation in PTCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855362     DOI: 10.1007/s12032-012-0315-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation.

Authors:  Nadia Felli; Laura Fontana; Elvira Pelosi; Rosanna Botta; Desirée Bonci; Francesco Facchiano; Francesca Liuzzi; Valentina Lulli; Ornella Morsilli; Simona Santoro; Mauro Valtieri; George Adrian Calin; Chang-Gong Liu; Antonio Sorrentino; Carlo M Croce; Cesare Peschle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

2.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

3.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Authors:  Zhibin Hu; Xi Chen; Yang Zhao; Tian Tian; Guangfu Jin; Yongqian Shu; Yijiang Chen; Lin Xu; Ke Zen; Chenyu Zhang; Hongbing Shen
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

4.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Authors:  Michela Garofalo; Gianpiero Di Leva; Giulia Romano; Gerard Nuovo; Sung-Suk Suh; Apollinaire Ngankeu; Cristian Taccioli; Flavia Pichiorri; Hansjuerg Alder; Paola Secchiero; Pierluigi Gasparini; Arianna Gonelli; Stefan Costinean; Mario Acunzo; Gerolama Condorelli; Carlo Maria Croce
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

5.  BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.

Authors:  Li-Qun Gu; Feng-Ying Li; Lin Zhao; Yun Liu; Xun-Xiong Zang; Tian-Xiang Wang; Hui-Ping Chen; Guang Ning; Yong-Ju Zhao
Journal:  Thyroid       Date:  2009-04       Impact factor: 6.568

Review 6.  Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  Endocr J       Date:  2008-08-13       Impact factor: 2.349

Review 7.  Role of NF-kappaB in thyroid cancer.

Authors:  Francesco Pacifico; Antonio Leonardi
Journal:  Mol Cell Endocrinol       Date:  2009-10-30       Impact factor: 4.102

8.  MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle.

Authors:  Rosa Visone; Lucia Russo; Pierlorenzo Pallante; Ivana De Martino; Angelo Ferraro; Vincenza Leone; Eleonora Borbone; Fabio Petrocca; Hansjuerg Alder; Carlo Maria Croce; Alfredo Fusco
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

Review 9.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

10.  Presence of BRAF V600E in very early stages of papillary thyroid carcinoma.

Authors:  Clara Ugolini; Riccardo Giannini; Cristiana Lupi; Giuliana Salvatore; Paolo Miccoli; Agnese Proietti; Rossella Elisei; Massimo Santoro; Fulvio Basolo
Journal:  Thyroid       Date:  2007-05       Impact factor: 6.568

View more
  17 in total

1.  Anti-miRNA-221 sensitizes human colorectal carcinoma cells to radiation by upregulating PTEN.

Authors:  Qi Xue; Kai Sun; Hai-Jun Deng; Shang-Tong Lei; Jing-Qing Dong; Guo-Xin Li
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 2.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

Review 3.  MicroRNA expression profiles in the management of papillary thyroid cancer.

Authors:  James C Lee; Justin S Gundara; Anthony Glover; Jonathan Serpell; Stan B Sidhu
Journal:  Oncologist       Date:  2014-10-16

4.  Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.

Authors:  Patricia Aragon Han; Hyun-seok Kim; Soonweng Cho; Roghayeh Fazeli; Alireza Najafian; Hunain Khawaja; Melissa McAlexander; Benzon Dy; Meredith Sorensen; Anna Aronova; Thomas J Sebo; Thomas J Giordano; Thomas J Fahey; Geoffrey B Thompson; Paul G Gauger; Helina Somervell; Justin A Bishop; James R Eshleman; Eric B Schneider; Kenneth W Witwer; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2016-03-07       Impact factor: 6.568

5.  Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.

Authors:  Xiabin Lan; Wei Sun; Ping Zhang; Liang He; Wenwu Dong; Zhihong Wang; Siming Liu; Hao Zhang
Journal:  Tumour Biol       Date:  2015-11-26

6.  Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis.

Authors:  Zhihong Wang; Hao Zhang; Ping Zhang; Jing Li; Zhongyan Shan; Weiping Teng
Journal:  Med Oncol       Date:  2013-04-23       Impact factor: 3.064

Review 7.  BRAF Mutation in Hairy Cell Leukemia.

Authors:  Ahmad Ahmadzadeh; Saeid Shahrabi; Kaveh Jaseb; Fatemeh Norozi; Mohammad Shahjahani; Tina Vosoughi; Saeideh Hajizamani; Najmaldin Saki
Journal:  Oncol Rev       Date:  2014-09-23

8.  Molecular pathways associated with aggressiveness of papillary thyroid cancer.

Authors:  Salvatore Benvenga; Christian A Koch
Journal:  Curr Genomics       Date:  2014-06       Impact factor: 2.236

9.  Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma.

Authors:  Zhihong Wang; Hao Zhang; Liang He; Wenwu Dong; Jing Li; Zhongyan Shan; Weiping Teng
Journal:  Onco Targets Ther       Date:  2013-03-28       Impact factor: 4.147

10.  Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies.

Authors:  Jie Yang; Jia-yi Zhang; Jing Chen; Yang Xu; Ning-hong Song; Chang-jun Yin
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.